Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
OGEN | US
0.06
6.70%
Healthcare
Biotechnology
30/06/2024
09/03/2026
0.96
0.88
0.98
0.88
Oragenics Inc. a development-stage company engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1 an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04 a weight loss candidate; and SMaRT Replacement Therapy a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen Inc. Oragenics Inc. was incorporated in 1996 and is headquartered in Tampa Florida.
View LessLow Market Beta (-0.4 to 0.8)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
94.6%1 month
98.1%3 months
88.2%6 months
77.2%-
-
7.57
-
-
0.21
105.83
-
-19.64M
10.12M
10.12M
-
-263.29K
-
-91.30
-454.72
0.25
1.45
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.38
Range1M
0.40
Range3M
0.42
Rel. volume
0.63
Price X volume
267.48K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| ICU | ICU | Biotechnology | 2.64 | 11.07M | 4.76% | n/a | -45.50% |
| Adial Pharmaceuticals Inc | ADIL | Biotechnology | 1.72 | 11.02M | -6.01% | n/a | 0.00% |
| Klotho Neurosciences Inc. | KLTO | Biotechnology | 0.4711 | 10.98M | 2.73% | n/a | 0.00% |
| Outlook Therapeutics Inc | OTLK | Biotechnology | 0.4476 | 10.59M | 8.12% | n/a | -39.11% |
| Cocrystal Pharma Inc | COCP | Biotechnology | 1.03 | 10.48M | 1.98% | n/a | 10.24% |
| HOOKIPA Pharma Inc | HOOK | Biotechnology | 1.05 | 10.39M | 3.96% | n/a | 5.69% |
| Cadrenal Therapeutics Inc. Common Stock | CVKD | Biotechnology | 8 | 9.46M | -3.38% | n/a | 0.22% |
| Alzamend Neuro Inc. Common Stock | ALZN | Biotechnology | 2.1 | 9.40M | 6.06% | n/a | 0.00% |
| BioAtla Inc. | BCAB | Biotechnology | 0.1891 | 9.14M | 12.69% | n/a | 5.30% |
| VYNE Therapeutics Inc | VYNE | Biotechnology | 0.5902 | 8.71M | -0.82% | 1.29 | 0.19% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 3.98 | 6.06M | -4.33% | n/a | 204.46% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.47 | 3.75M | -0.67% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.39 | 3.71M | -1.76% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.46 | 1.36M | 2.93% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.008 | 737.72K | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.21 | 0.53 | Cheaper |
| Ent. to Revenue | 105.83 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 7.57 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 88.17 | 72.80 | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 10.12M | 3.66B | Emerging |